SCIMITAR EQUITY RESEARCH ISSUES REVIEW OF PROTEIN POLYMER TECHNOLOGIES, Inc.

 

BOSTON, June 6 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar)
issues an Informational Review of Protein Polymer Technologies, Inc. (OTC
Bulletin Board: PPTI.OB), entitled, "Prioritization and Innovation Bring
Products Forward." This review is available at our website:
http://www.scimitarequity.com.
Scimitar Equity Research, Inc. provides sponsored equity research of the
health sciences industry for the institutional and investment communities. We
certify that all the views expressed in this review, accurately reflect our
personal views about PPTI.OB (OTC BB) and its or their securities. No part of
our compensation was, is, or will be, directly or indirectly, related to the
specific recommendations or views contained in this review and we will not
have any investment banking relationships or personal investment in any
sponsored company. Investors are advised that this analysis and review is
issued solely for informational purposes and is not to be construed as an
offer to sell or the solicitation of an offer to buy. Scimitar was paid for
preparing this review. This analysis and review does not have regard to the
specific investment objectives, financial situation and the information
contained herein is based on sources that we believe to be reliable but is not
guaranteed by us as being accurate and does not purport to be a complete
statement or summary of the available data. Any opinions expressed are
statements of our own judgment as of the date of publication and are subject
to change without notice. Please read all our important disclosures.

CONTACT:
Scimitar Equity Research, Inc.
Henry W. McCusker
Director of Research
phone: (617) 236-6396
fax: (617) 236-6397
e-mail:hwm@scimitarequity.com

SOURCE Scimitar Equity Research, Inc.
Web Site: http://www.scimitarequity.com

 

Contact

J. Thomas Parmeter, Ph.D. Chairman Protein Polymer Technologies, Inc. (858) 558-6064 info@ppti.com

About Protein Polmer Technologies

Protein Polymer Technologies, Inc., is a San Diego-based company focused on developing bioactive devices to improve medical and surgical outcomes. From its inception in 1988, PPTI has been a pioneer in protein design and synthesis, creating an extensive portfolio of proprietary biomaterials for use in the development of bioactive devices. These genetically engineered biomaterials are high molecular weight proteins, processed into products with physical and biological characteristics tailored to specific clinical performance requirements. Targeted products include urethral bulking agents for the treatment of stress urinary incontinence, dermal augmentation products for cosmetic and reconstructive surgery, surgical adhesives and sealants, scaffolds for wound healing and tissue engineering, and depots for local drug delivery. To date, PPTI has been issued twenty-six U.S. Patents on its core technology with corresponding issued and pending patents in key international markets.

Safe Harbor

This press release contains forward-looking statements that are based on management’s views and expectations. Actual results could differ materially from those expressed here; further, the Company is not obligated to comment specifically on those differences. Risks associated with the Company’s activities include raising adequate capital to continue operations scientific and product development uncertainties, competitive products and approaches, continuing collaborative partnership interest and funding, regulatory testing and approvals, and manufacturing scale up. The reader is encouraged to refer to the Company’s 2004 Annual Report Form 10-KSB, and other recent filings with the Securities and Exchange Commission, copies of which are available from the Company, to further ascertain the risks associated with the above statements.